• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症治疗中的固有免疫刺激

Innate Immune Stimulation in Cancer Therapy.

机构信息

Institute of Innate Immunity, University of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany.

Medizinische Klinik und Poliklinik 3, Klinikum rechts der Isar, Technische Universität München, Ismaningerstrasse 22, Munich 81675, Germany.

出版信息

Hematol Oncol Clin North Am. 2019 Apr;33(2):215-231. doi: 10.1016/j.hoc.2018.12.002. Epub 2019 Jan 9.

DOI:10.1016/j.hoc.2018.12.002
PMID:30832996
Abstract

The innate immune system has evolved as a first line of defense against invading pathogens and acts via classes of germline-encoded receptor systems to respond with proinflammatory cytokines. Innate immune cells, predominantly cells of the myeloid compartment, are capable of providing a potent basis for boosting adaptive immunity in malignant diseases. The authors review their current understanding of the molecular mechanisms whereby innate pattern recognition receptors participate in immunosurveillance of cancer cells. They discuss how innate effector mechanisms are currently being targeted pharmacologically and how improved understanding of the biology of these pathways is leading to novel immunotherapies of cancer.

摘要

天然免疫系统作为抵御入侵病原体的第一道防线而进化,通过胚系编码受体系统的类别来发挥作用,以产生促炎细胞因子。天然免疫细胞,主要是髓系细胞,能够为增强恶性疾病中的适应性免疫提供有力基础。作者回顾了他们目前对天然模式识别受体参与癌细胞免疫监视的分子机制的理解。他们讨论了目前如何通过药理学靶向天然效应机制,以及对这些途径的生物学的更好理解如何导致癌症的新免疫疗法。

相似文献

1
Innate Immune Stimulation in Cancer Therapy.癌症治疗中的固有免疫刺激
Hematol Oncol Clin North Am. 2019 Apr;33(2):215-231. doi: 10.1016/j.hoc.2018.12.002. Epub 2019 Jan 9.
2
Targeting Cytosolic Nucleic Acid-Sensing Pathways for Cancer Immunotherapies.靶向细胞溶质核酸感应途径的癌症免疫治疗。
Front Immunol. 2018 Apr 9;9:711. doi: 10.3389/fimmu.2018.00711. eCollection 2018.
3
The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance.先天免疫和适应性免疫在癌症中的相互作用塑造了癌症免疫监视的效率。
J Leukoc Biol. 2020 Jul;108(1):363-376. doi: 10.1002/JLB.3MIR0320-475R. Epub 2020 Apr 9.
4
Roles for Innate Immunity in Combination Immunotherapies.固有免疫在联合免疫疗法中的作用。
Cancer Res. 2017 Oct 1;77(19):5215-5221. doi: 10.1158/0008-5472.CAN-17-1340. Epub 2017 Sep 19.
5
Natural innate and adaptive immunity to cancer.天然固有免疫和适应性免疫与癌症。
Annu Rev Immunol. 2011;29:235-71. doi: 10.1146/annurev-immunol-031210-101324.
6
Enhancing Cancer Immunotherapy Via Activation of Innate Immunity.通过激活固有免疫增强癌症免疫疗法
Semin Oncol. 2015 Aug;42(4):562-72. doi: 10.1053/j.seminoncol.2015.05.012. Epub 2015 Jun 3.
7
Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways.癌症免疫疗法的潜在靶点:Toll样受体、视黄酸诱导基因样受体和干扰素基因刺激蛋白介导的天然免疫途径
Int J Mol Sci. 2017 Feb 14;18(2):404. doi: 10.3390/ijms18020404.
8
Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation.靶向肿瘤细胞和免疫检查点受体的治疗性抗体联合使用的原理:通过IgG1同种型免疫效应刺激来利用先天免疫和适应性免疫。
Cancer Treat Rev. 2018 Feb;63:48-60. doi: 10.1016/j.ctrv.2017.11.008. Epub 2017 Dec 2.
9
Multilayered Immunity by Tissue-Resident Lymphocytes in Cancer.癌症中组织驻留淋巴细胞的多层免疫
Annu Rev Immunol. 2024 Jun;42(1):647-677. doi: 10.1146/annurev-immunol-083122-043836. Epub 2024 Jun 14.
10
Cooperativity of adaptive and innate immunity: implications for cancer therapy.适应性免疫和固有免疫的协同作用:对癌症治疗的启示。
Cancer Immunol Immunother. 2011 Aug;60(8):1061-74. doi: 10.1007/s00262-011-1053-z. Epub 2011 Jun 9.

引用本文的文献

1
Phase Ib/II study of imprime PGG and pembrolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC): BTCRC LUN 15-017.Imprime PGG与帕博利珠单抗用于既往治疗的晚期非小细胞肺癌(NSCLC)患者的Ib/II期研究:BTCRC LUN 15-017
Transl Lung Cancer Res. 2024 Nov 30;13(11):2998-3009. doi: 10.21037/tlcr-24-346. Epub 2024 Nov 19.
2
Structural characterization of a novel Fr. polysaccharide and its immunity activity in BALB/c mice.一种新型法国多糖的结构表征及其在BALB/c小鼠中的免疫活性
RSC Adv. 2020 Aug 17;10(51):30254-30264. doi: 10.1039/d0ra05176d.
3
Therapeutic Development by Targeting the cGAS-STING Pathway in Autoimmune Disease and Cancer.
通过靶向自身免疫性疾病和癌症中的cGAS-STING通路进行治疗性开发
Front Pharmacol. 2021 Nov 15;12:779425. doi: 10.3389/fphar.2021.779425. eCollection 2021.
4
Development of a Novel Prognostic Signature Based on Antigen Processing and Presentation in Patients with Breast Cancer.基于抗原加工和呈递的新型乳腺癌预后标志物的建立。
Pathol Oncol Res. 2021 Apr 1;27:600727. doi: 10.3389/pore.2021.600727. eCollection 2021.
5
BRD4 inhibition exerts anti-viral activity through DNA damage-dependent innate immune responses.BRD4 抑制通过依赖 DNA 损伤的先天免疫反应发挥抗病毒活性。
PLoS Pathog. 2020 Mar 24;16(3):e1008429. doi: 10.1371/journal.ppat.1008429. eCollection 2020 Mar.
6
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy.嵌合抗原受体在癌症治疗设计中的局限性。
Cells. 2019 May 17;8(5):472. doi: 10.3390/cells8050472.